Sintx Technologies, Inc. (SINT) · Nov 5, 2026 · Earnings
Beat — Revenue $2.19M vs ~$1.33M consensus; diluted EPS $(0.24) vs ~$(0.31) consensus
SINTX earnings beat revenue and EPS expectations, with gross margin reaching 62% and operating losses cut sharply. The commercial ramp is real, but funding remains necessary.
SINTX is moving from a development-heavy biomaterials company toward commercial execution, using industrial ceramics sales to fund a broader push into orthopedic implants, wound care, and other silicon-nitride applications. Earlier in 2026, management guided to roughly $0.9 million-$1.1 million of Q3 revenue after announcing about $3.2 million of industrial purchase orders, while the company was still building its SiNAPTIC distribution channel and managing liquidity.
| Figure | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Total revenue (Income Statement) | $2.19M (+952.9%) | $0.208M | $1.33M |
| Gross profit (Income Statement) | $1.36M (+1,364.5%) | $0.093M | |
| Gross margin (Financial Highlights) | 62% | 45% | |
| Operating expenses (Income Statement) | $3.00M (-13.1%) | $3.45M | |
| Net loss (Income Statement) | $(1.60)M (-55.0%) | $(3.54)M | |
| Diluted EPS (Income Statement) | $(0.24) | $(1.19) | $(0.31) |
| Cash and equivalents (Balance Sheet) | $2.005M | $4.140M at Dec. 31, 2025 |
The quarter was a genuine earnings beat, not just year-over-year improvement. Revenue of $2.19 million exceeded the published consensus of roughly $1.33 million, while diluted EPS of $(0.24) was better than the roughly $(0.31) expectation. The result was already partly known because SINTX disclosed preliminary Q3 revenue of approximately $2.2 million on October 1, so the final release confirms the magnitude rather than unveiling a surprise.
The quality of the revenue growth improved materially. Gross margin reached approximately 62%, up from 45%, while operating expenses fell 13%; that combination cut the operating loss roughly in half. The filing attributes the margin expansion to improved pricing, higher manufacturing volumes, and better production efficiency. 〔0〕
This advances the commercial-transition story, but does not complete it. Product revenue supplied $2.09 million of the quarter's $2.19 million total, indicating that the milestone was driven primarily by shipments rather than grants. However, the filing still describes the SiNAPTIC rollout as initial commercial sales, and its future medical-platform opportunities remain development or preclinical programs rather than established revenue streams. 〔1〕
Liquidity remains the central constraint. SINTX ended September with about $2.0 million of cash, then received another approximately $2.0 million from warrant exercises after the quarter; that financing was triggered by reaching the $2 million revenue milestone. The company also says it continues to pursue additional financing alternatives, so the improved operating performance has not yet made the business self-funding. 〔2〕
The next proof point is whether this becomes repeatable revenue. The company has started large-animal studies for silicon-nitride-treated sutures and wound dressings, expected to finish in the first quarter of 2027, but the more immediate business test is whether industrial orders and early orthopedic commercialization can sustain sales without repeated capital support. 〔3〕
Bottom line: This was a better-than-expected quarter that strengthens SINTX's commercial-execution story, especially through higher margins and lower losses. It matters, but the company is still early-stage, loss-making, and dependent on financing while it works to turn one strong revenue milestone into a durable business.
Large-animal wound-care study completion, Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!